This bill (SB 35) limits employer liability when an employee's criminal record for drug addiction-related offenses or diseases is expunged. It requires the state to create a database tracking these expungements and mandates courts to check this database in cases involving such employees. Employers are not required to provide health insurance or cover health care costs related to drug addiction or addiction-related diseases if the employee's record was expunged. The law specifically applies to employees participating in "return to work initiatives" for recovering addicts and does not affect employers' obligations for non-addiction-related issues.
HB 4715 removes the requirement for nurse practitioners and physician assistants in West Virginia to practice under direct physician supervision. The bill repeals sections §30-3E-10a and §30-3E-11 of the state code, which previously mandated supervision, and amends related provisions to allow these providers to practice independently. This change directly affects licensed nurse practitioners and physician assistants who will no longer need a collaborating physician's oversight for their scope of practice. The bill focuses on updating regulatory language to eliminate supervision barriers, without altering prescribing rules or other practice parameters.
HB 4075 requires all health insurers in West Virginia to cover biodentical hormones when medically necessary and prescribed by a licensed physician after a thorough evaluation of the patient's symptoms or test results. The bill applies to all health insurance policies, including group plans, nonprofit corporation contracts, hospital service policies, health care corporations, and health maintenance organizations (HMOs). Insurers must provide this coverage on an expense-incurred basis starting January 1, 2026. This policy change directly affects patients seeking hormone treatment and insurers offering health coverage in the state.
SB 361 authorizes the West Virginia Board of Pharmacy to implement a rule regarding pharmacist recovery networks, which are programs enabling pharmacists to provide medication-assisted treatment for opioid use disorder. The rule, previously drafted and modified to address legislative concerns, is now formally approved by law. This procedural bill directly affects pharmacists and pharmacies by allowing the Board to establish standards for participation in recovery networks. It does not alter the rule's content but enables its implementation as part of pharmacy practice regulations.
This bill creates a special revenue account within West Virginia's Department of Human Services to reduce out-of-state residential placements for children in state care. It establishes a Commission with representatives from child welfare, behavioral health, juvenile justice, education, and court systems to study current placement practices and develop strategies to expand in-state treatment capacity. Key provisions require the Commission to report annually with an implementation plan targeting a 50% reduction in out-of-state placements within three years, while promoting collaboration between agencies through joint funding proposals and improved access to in-state facility data. The bill directly affects children in foster care or juvenile justice systems, their families, and state agencies responsible for their care.
HB 4626 establishes a West Virginia grant program to fund U.S. Food and Drug Administration (FDA) drug development trials using ibogaine, a substance being studied for treating opioid use disorder and other neurological/mental health conditions. The program requires applicants (e.g., pharmaceutical companies or research organizations) to demonstrate capacity to conduct FDA trials, secure approval for ibogaine as a medication, and commit to establishing a state presence, securing insurance coverage, and ensuring treatment access for uninsured patients. Applicants must submit detailed trial designs, safety protocols, and plans for intellectual property rights and post-approval implementation, with grants administered through a state selection committee. The bill does not approve ibogaine but aims to accelerate its development pathway through state-funded trials.
HB 4721 would amend West Virginia's drug scheduling law to automatically remove a specific form of psilocybin - crystalline polymorph psilocybin - from Schedule I if approved by the FDA and DEA for medical use. This change would apply only to the crystalline form of psilocybin that receives federal approval, not to other forms or uses of psilocybin. The bill creates a direct pathway for this specific approved form to be legally accessible for medical purposes without requiring additional state legislation. It does not change current restrictions on other psilocybin forms or recreational use.
SB 599 prohibits the use of abortifacients (drugs intended to cause an abortion) in West Virginia, except in medical emergencies that pose a serious risk to a patient's life or major bodily functions. The bill imposes criminal penalties for prescribing, sending, or dispensing abortifacients within the state and allows for revocation of medical licenses for violating healthcare providers. It also requires informed consent for abortions in medical emergencies and mandates the state health department to publish public information and operate a hotline on abortion services. This bill directly affects healthcare providers, pharmacies, and entities involved in distributing abortion-related medications.
SB 189 establishes a licensing framework for certified professional midwives (CPMs) in West Virginia, requiring a license from the West Virginia Board of Registered Nurses to practice midwifery or use the title "licensed midwife." The bill defines key terms like "midwife," "licensed midwife," and "collaboration" with physicians, clarifying that midwives provide primary maternity care but must refer clients needing higher medical care. It sets requirements for licensure, continuing education, temporary permits, and prohibits unlicensed practice, while outlining responsibilities for midwives including client confidentiality and proper referrals. This bill directly affects midwives seeking to legally practice and their clients by creating standardized regulations for midwifery care in the state.
HB 4681 would allow West Virginia residents injured by Covid-19 vaccines to sue pharmaceutical companies for damages without limits on the amount they can recover. Currently, drug manufacturers typically avoid liability for vaccine injuries by providing warnings to healthcare providers (the "learned intermediary" rule), but this bill removes that protection specifically for Covid-19 vaccines. The law change would let injured individuals seek full compensation in court for vaccine-related harm. This exception applies only to Covid-19 vaccines and does not affect liability rules for other drugs or medical devices.
